Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
This Bitcoin-focused microcap is building a treasury strategy centered on accumulating BTC (click to learn more) Laser Photonics Reports Full Year Total Net Sales Increase of 144% in Q4 2025 Financial Results (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Immunic Inc IMUX

Healthcare Biotechnology
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe... see more

Current News (NDAQ:IMUX)

Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December

PR Newswire November 26, 2025

Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

PR Newswire November 13, 2025

Immunic to Participate in Industry and Investor Conferences in November

PR Newswire October 29, 2025

Immunic to Participate in Scientific and Investor Conferences in October

PR Newswire October 1, 2025

Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis

PR Newswire September 25, 2025

Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis

PR Newswire September 9, 2025

Immunic to Participate in Investor and Scientific Conferences in September

PR Newswire September 4, 2025

Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

PR Newswire August 7, 2025

Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis

PR Newswire June 24, 2025
View More News ››

Opinion & Analysis (NDAQ:IMUX)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:IMUX)

oh wow

a 16$ penny stock. this company is going to get shorted to death! what a joke.
Dontgrtfooled - April 19, 2019
View more Bullboard ››

Avrupa Minerals Ltd.

Avrupa Minerals Ltd.

Avrupa Minerals Ltd., a junior exploration and development company, engages in the acquisition and exploration of mineral ...
View More »

Podcasts